Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin for glycaemic variability in type 1 diabetes
ACTRN12613001056785Phase 4Completed
- Sponsor
- Baker Heart and Diabetes Institute
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Vildagliptin add-on with Placebo add-on (2 arms). Primary endpoint: Glycaemic variability. Started Dec 2013; status: completed.
02
Drugs
vildagliptin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on ACTRN12613001056785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613001056785.